According to filings with the U.S. Securities and Exchange Commission, TJM Labs is raising up to $9,999,987.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About TJM Labs
TJM Labs helps pharmacies eliminate manual, repetitive work with AI-driven automation. Our solutions handle prescription intake, fax processing, demographic updates, and reporting seamlessly within existing pharmacy systems. The result is higher accuracy, faster throughput, and pharmacy staff freed to focus on patients. What sets us apart is our Dual-Expert Model. Every implementation pairs a pharmacist and an engineer to ensure clinical accuracy and technical precision. This hands-on approach guarantees workflows are tailored, compliant, and resilient instead of relying on one-size-fits-all software. Today, our AI agents support pharmacies processing tens of thousands of prescriptions each week. By combining deep healthcare expertise with advanced technology, TJM Labs delivers measurable ROI such as lower costs, fewer errors, and scalable growth, while keeping patient care at the center.

To learn more about TJM Labs, visit https://tjmlabs.com/
TJM Labs Linkedin Page: https://www.linkedin.com/company/tjm-labs/

Contact:
Jonathan Adly, Chief Executive Officer
347-861-1051
https://www.linkedin.com/in/jonathan-adly/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.